# Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

> **NCT03484819** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Primary Mediastinal Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Primary Mediastinal Large B-Cell Lymphoma

## Interventions

- **DRUG:** Copanlisib Hydrochloride
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03484819
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-13
- **Primary completion:** 2022-11-18
- **Final completion:** 2024-08-14
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2025-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03484819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03484819, "Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03484819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*